// App-Quantinova.ai

5082 : Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP).

Researchers

Presenter

  • Fred Saad

Principal Investigators

  • Daniel Keizman

  • Joe M. O'Sullivan

  • Joan Carles

  • Manfred Wirth

  • Silke Gillessen

  • Camilla Thellenberg-Karlsson

  • Kurt Miller

  • Marcello Tucci

  • Giovanni Paganelli

  • Giuseppe Procopio

  • Jeremy Gratt

  • Monica Seger

  • Sten Nilsson

  • Daniel Heinrich

Medical Centers

  • University of Montreal Hospital Center, Montreal, QC, Canada

  • Meir Medical Center, Kfar-Saba, Israel

  • Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • University Hospital Carl Gustav Carus, Dresden, Germany

  • Kantonsspital St Gallen, St Gallen, Switzerland

  • Umea University, Umea, Sweden

  • Charite Berlin, Berlin, Germany

  • San Luigi Hospital, Orbassano (Turin), Italy

  • IRST-IRRCS Cancer Center, Meldola, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Pharmaceuticals Division of Bayer, Whippany, NJ

  • Karolinska University Hospital, Stockholm, Sweden

  • Akershus University Hospital, Lorenskog, Norway

Locations

  • Ireland

  • Canada

  • Italy

  • Norway

  • Germany

  • Spain

  • Switzerland

  • United States

  • Israel

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Radium-223 Dichloride

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multinational

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved